MedTrace Logo

Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes

NCT00411411 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2014-08-13

Study results available
· View outcomes & findings →

Summary

We wish to evaluate the effect of long term treatment with a DPP-IV inhibitor on the function of the incretin hormones

Hypothesis We hypothesize that that a gradual improvement in metabolic control induced by DPP-IV inhibitor (Januvia®) treatment significantly ameliorates the impaired secretion and potency of GLP-1 and leads to a restoration of the lost action of GIP.

Conditions

Interventions

DRUG

Januvia

200 mg t.i.d

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Kasper Aaboe, MD · Gentofte University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-02-28
Completion
2009-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00411411 on ClinicalTrials.gov